Sarepta Therapeutics (SRPT) Heads To Morgan Stanley, Is Most Of The Upside Already Priced In?
Sarepta Therapeutics (SRPT) is back in focus after the company was listed to present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on September 14, 2026.
The upcoming Morgan Stanley appearance comes after a mixed run for Sarepta Therapeutics, with the share price down 9.11% over the past week but up 29.59% over 90 days and a 1-year total shareholder return of 17.06%, alongside a steep 3-year total shareholder loss of 82.68%. This suggests that near-term momentum has picked up even as longer-term holders have experienced heavy declines.
Scan Sarepta Therapeutics alongside other rare disease and biotech players that could be setting up for the next move using our curated 15 high quality undiscovered gems.
After a sharp 90 day rebound, but with a deep 3 year loss still hanging over Sarepta Therapeutics, the real tension now sits in the valuation work. Is most of the recovery already priced in, or is meaningful upside still on the table?
Most Popular Narrative: 6% Undervalued
The most followed valuation narrative now pegs Sarepta Therapeutics at a fair value of about $21.65, only slightly above the last close at $20.45. This suggests the current price already reflects a good chunk of what that framework is assuming.
The analysts have a consensus price target of $21.65 for Sarepta Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $38.0, and the most bearish reporting a price target of just $5.0.
See why 40 investors see Sarepta Therapeutics as 6% undervalued.
Result: Fair Value of $21.65 (UNDERVALUED)
Still, the Sarepta Therapeutics story can shift quickly if ELEVIDYS safety concerns deepen or if administrative hurdles keep delaying gene therapy treatment and revenue recognition.
Find out about the key risks to this Sarepta Therapeutics narrative.
Next Steps
Mixed signals on Sarepta Therapeutics can pull you in both directions, so move quickly to review the full picture and weigh both the potential upside and the issues that keep investors cautious by checking the 2 key rewards and 1 important warning sign.
Looking for more Sarepta Therapeutics sized ideas?
If Sarepta Therapeutics has you thinking about what else might be hiding in plain sight, use this moment to scan wider opportunities before the best setups move on.
- Target steadier potential by focusing on balance sheet strength and fundamentals through our curated list of solid balance sheet and fundamentals (23 results).
- Hunt for quality at a sensible price by reviewing companies that look attractively priced across the 32 high quality undervalued stocks.
- Prioritise resilience and sleep-better-at-night holdings by working through the hand picked 11 resilient stocks with low risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com